Zhengzhou University

LexinFintech Holdings Ltd. Appoints Chief Risk Officer

Retrieved on: 
Monday, December 4, 2023
Zhengzhou University, Risk, LX, Statistics, Zhejiang Gongshang University, North China, Overalls, Risk management, Ant Group

SHENZHEN, China, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced that its board of directors has appointed Mr. Zhanwen Qiao as the Company’s Chief Risk Officer, effective on 4th Dec, 2023.

Key Points: 
  • SHENZHEN, China, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced that its board of directors has appointed Mr. Zhanwen Qiao as the Company’s Chief Risk Officer, effective on 4th Dec, 2023.
  • Mr. Qiao has deeply involved in the entire process of building and iterating Ant Group's consumer credit risk management system, with his extensive experience in building risk management teams, innovating risk management technologies, and managing consumer credit risks.
  • “We are delighted to welcome Zhanwen as our new Chief Risk Officer,” said Mr. Jay Wenjie Xiao, Lexin’s chairman and Chief Executive Officer.
  • “We look forward to Zhanwen’s professional skills and extensive experience in risk management space to assist us in achieving more breakthroughs in risk management capabilities and unfolding a new chapter for Lexin’s risk management.”
    “I am thrilled to take on the role of the Chief Risk Officer of Lexin,” Mr. Qiao stated.

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Retrieved on: 
Monday, August 7, 2023
Second Affiliated Hospital of Xinjiang Medical University, Visual analogue scale, Migraine, Depression, Prevalence, HHS, PSQI, MSQ, Clinical trial, World Health Organization, DSM-IV codes, Department of Neurology, Xuanwu hospital, Zhengzhou University, VAS, HAMA, Trial of the century, MDE, Pain, MDD, Patient, Grammatical mood, Pittsburgh Sleep Quality Index, Research, The Rheumatoid Arthritis Quality of Life Questionnaire, WHO, International Journal of Research in Marketing, Pharmaceutical industry, Brain

As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.

Key Points: 
  • As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.
  • The migraine study follows the Company’s recent clinical study in depression, which demonstrated statistically significant improvements among patients.
  • Mark White, CEO of Nexalin Technology, stated, "Research and Markets estimates the migraine and depression markets at roughly $3.9 billion and $11.2 billion, respectively.
  • We look forward to conducting additional clinical trials in new indications – many of which will be fully funded by Wider, our new JV partner.”

Ronovo wins resounding KOL accolades in latest Carina™ RAS Platform animal labs

Retrieved on: 
Wednesday, March 1, 2023
Hardware, Other Health, Technology, Robotics, Surgery, General Health, Professional Services, Medical Devices, Hospitals, Venture Capital, Other Technology, Science, Veterinary, Other Science, Research, Health, Zhengzhou University, Cadaver, Phlebotomy, KOL, Jiaotong University, Gynaecology, Urology, Hospital, RAS, Patient, Salpingo-oophorectomy, Laparoscopy, Hysterectomy, Surgeon, Operating, Fudan University, Renal artery, Multimedia, Dissection, Bleeding, MIS, Instrument, Uterine artery, Dentistry, Pharmaceutical industry

Recently, Ronovo Surgical invited top gynecology and urology surgeons to evaluate the performance of its newly unveiled Carina™ RAS Platform, the first modular robotic-assisted surgery (RAS) platform developed in China for laparoscopic procedures.

Key Points: 
  • Recently, Ronovo Surgical invited top gynecology and urology surgeons to evaluate the performance of its newly unveiled Carina™ RAS Platform, the first modular robotic-assisted surgery (RAS) platform developed in China for laparoscopic procedures.
  • View the full release here: https://www.businesswire.com/news/home/20230301005036/en/
    Image: Carina™ RAS Platform being configured for animal lab.
  • The small footprint of each bedside module is designed to improve the surgical team’s ability to efficiently utilize precious OR space.
  • KOL feedback from these latest evaluations represents a major milestone in readiness for human clinical trials, which are planned for later this year.

Bionano Genomics Announces a Publication From the First Affiliated Hospital of Zhengzhou Highlighting the Utility of OGM

Retrieved on: 
Thursday, May 12, 2022
Dai, Online, Software, NGS, Company, Pregnancy loss, CNV, Genome, Medicine, Private Securities Litigation Reform Act, Infertility, U.S. Securities and Exchange Commission, Nasdaq, Doctor of Philosophy, First Affiliated Hospital of Xinjiang Medical University, Genetic testing, Biology, Patient, Solution, Workflow, Cytogenetics, COVID-19, Genetics, Hospital Insurance and Diagnostic Services Act, Method, Research, SAN, Genetic distance, Chromosome, Lineagen, Forward-looking statement, Genomics, Zhengzhou University, Adoption, Karyotype, Autism, Chromosomal translocation, OGM, The First Affiliated Hospital of Wenzhou Medical University, Security (finance), Annual report, GLOBE, Medical imaging, FISH, Central China

Analysis of this abnormality may be helpful in the screening and analysis of embryos prior to implantation, as part of fertility treatment.

Key Points: 
  • Analysis of this abnormality may be helpful in the screening and analysis of embryos prior to implantation, as part of fertility treatment.
  • We believe this paper highlights the growing validation of OGM in different applications for clinical research in cytogenetics.
  • The work by Dr. Kong and his team at Zhengzhou University further extends this validation and highlights the utility of OGM.
  • The Companys mission is to transform the way the world seesthe genome through OGM solutions, diagnostic services and software.

Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic

Retrieved on: 
Monday, May 9, 2022
Division, STAR, Laboratory, Selective, ATP, National, Center for Biologics Evaluation and Research, Pharmacology, TCR, Physical Sciences-Oncology Centers, Oncology, Merck Serono, Immune system, Breast cancer, Patient, National Cancer Institute, Program, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Novartis, Center, Cornell University, Head, NCI, Therapy, Senior, IND, Cell, Doctor of Philosophy, Gene, Associate, David Kerr (oncologist), Publication, Veteran, MBA, Growth, Zhengzhou University, Multimedia, CAR, Lymphoma, Molecular biology, Food, Biotechnology, Cancer, Harvard Medical School, Heel, Pharmaceutical industry, Vaccine, Immunology, Organogenesis, Tissue, Research, Medicine

CAMBRIDGE, Mass., May 9, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the Vβ chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today announced the appointment of Ke Liu, M.D., Ph.D., as Chief Development Officer, as well as Bruce Chabner, M.D., as Senior Strategic Advisor. Dr. Liu will lead Marengo's clinical development and regulatory strategy, while Dr. Chabner will serve in an advisory capacity to the Marengo leadership team. As seasoned veterans of oncology drug development, Dr. Liu and Dr. Chabner will bring their significant expertise to Marengo as the company advances its STAR (Selective T Cell Activation Repertoire) platform to clinical trials in patients.

Key Points: 
  • Dr. Liu will lead Marengo's clinical development and regulatory strategy, while Dr. Chabner will serve in an advisory capacity to the Marengo leadership team.
  • "Ke's clinical and regulatory expertise in oncology and Bruce's instrumental contribution to cancer research have yielded unparalleled breakthroughs in the field.
  • The addition of such well-respected experts in the oncology space further supports progress of Marengo's novel T cell therapeutics into the clinic."
  • "I am thrilled to be joining Marengo at a key inflection point for the company's growth," said Dr. Liu.

Philips delivers Q4 sales of EUR 4.9 billion and income from continuing operations of EUR 139 million; Adjusted EBITA margin amounts to 13.1%, operating cash flow is EUR 720 million; good demand drives mid-single-digit order intake growth

Retrieved on: 
Monday, January 24, 2022
Spectral, Personal health record, Algorithm, Zhengzhou University, Science and technology in Asia, EUR, The First Affiliated Hospital of Wenzhou Medical University, Respironics, AI, Philips, Medical imaging, Personal, Technology, CDP, IVUS, COVID-19, ISO, Adoption, Climate change, Treatment, FDA, Hospital, Biotelemetry, Sonicare, Comparable, Hospital, patients, health, territories, Stiftung Warentest, Diagnosis, Growth, Income, Share repurchase, Solution, Health, Program, CT, Workflow, Machine learning, Acquisition, First Affiliated Hospital of Xinjiang Medical University, VOC, Multan Institute of Cardiology, Bed, ECG, Â, DreamSTATE, Infection, Film, Commercial property, Pharmaceutical industry, Fine chemical, Medical device, Cassette tape, Adjustment, Ultrasound, Group

This further builds on the high-single-digit Group comparable order intake growth in 2020, resulting in an all-time-high order book.

Key Points: 
  • This further builds on the high-single-digit Group comparable order intake growth in 2020, resulting in an all-time-high order book.
  • Based on good customer demand and our growing order book, we expect to resume our growth and margin expansion trajectory in the course of 2022.
  • For the Group, we target 3-5% comparable sales growth and a 40-90 basis-points improvement in Adjusted EBITA margin.
  • For the full year, the Diagnosis & Treatment businesses recorded 8% comparable sales growth and an Adjusted EBITA margin of 12.4%.

Secoo Announces Board Changes

Retrieved on: 
Tuesday, December 28, 2021
Securities Exchange Act of 1934, Growth, Graduate School of Chinese Academy of Social Sciences, Annual report, SECO, Private Securities Litigation Reform Act, Stock, U.S. Securities and Exchange Commission, Board, App Store (iOS/iPadOS), GLOBE, Company, NASDAQ, Terminology, Securities Act of 1933, Graduate school, Board of directors, Tsinghua University, Zhengzhou University, Social science, Audit, Security (finance), Secoo

BEIJING, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Secoo Holding Limited (Secoo or the Company) (NASDAQ: SECO), Asias leading online integrated upscale products and services platform, today announced that its Board of Directors (the Board) has approved the appointment of Mr. Jianji Liu to the Board as an independent director and the resignation of each of Ms. Qi Zhu and Mr.Jian Wang from the post as a director of the Company, all effective December 28, 2021.

Key Points: 
  • BEIJING, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Secoo Holding Limited (Secoo or the Company) (NASDAQ: SECO), Asias leading online integrated upscale products and services platform, today announced that its Board of Directors (the Board) has approved the appointment of Mr. Jianji Liu to the Board as an independent director and the resignation of each of Ms. Qi Zhu and Mr.Jian Wang from the post as a director of the Company, all effective December 28, 2021.
  • We thank each of Ms. Qi Zhu and Mr. Jian Wang for the contribution to our Board during their respective tenures, said Mr. Richard Rixue Li, Chairman and Chief Executive Officer of Secoo.
  • We look forward to working with him as we further grow our business and maximize value for all Secoo stakeholders.
  • Secoo Holding Limited (Secoo) is Asias leading online integrated upscale products and services platform.